Grants Search Results

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

Modern therapies such as stem cell transplant and immune therapy have made high-risk neuroblastoma a survivable disease for some children, but little is known about the chronic health issues experienced by survivors. In order to ensure that future treatments address both the chance and the quality of cure, this consortium aims to examine the impact of neuroblastoma therapy on survivors' growth, pubertal development and long-term health. This grant is generously supported by the "Just Do It...…and be done with it" Hero Fund created in honor of Sara Martorano who doesn't let anything dim her sparkle and has a compassionate heart and smile. It also celebrates the courage of all cancer kids through treatment and the support of their family and friends.

Dr. French's research focuses on a deadly cancer of children and young adults called NUT midline carcinoma. A while back Dr. French discovered the cancer protein that causes this disease, called BRD4-NUT. This discovery led to the development of inhibitors to BRD4 that are now being used to treat NUT midline carcinoma and this has expanded to the treatment of more common cancers in clinical trials. However, NUT midline carcinoma remains incurable. Recently, Dr. French discovered an additional and completely new protein that associates with BRD4-NUT, called a ZNF532, that helps BRD4-NUT cause this cancer. This research aims to understand how this new cancer protein contributes to the malignancy in this disease.

Retinoblastoma is a cancer of the eye in children that can cause blindness or death. New therapies are needed to combine with existing drugs to save vision, eyes, and lives. Dr. Corson has developed a new chemical that blocks abnormal blood vessel growth in the eye without side effects. By blocking new blood vessel formation, we could starve a growing retinoblastoma tumor of oxygen and nutrients and stop its growth. To determine this, Dr. Corson's research aims to test this new chemical in a model of retinoblastoma, both alone and in combination with an existing drug.

Graft-versus-host Disease (GvHD) is a common devastating side-effect of bone marrow transplantation. More than 50% of children suffer from moderate to life-threatening GvHD after bone marrow transplantation. GvHD results when the primary leukemia-fighting cells in the transplants become overzealous and begin to attack not only the leukemia, but also the patient’s skin, intestines, liver, and mucosa. Dr. Choi has demonstrated that modulating a gene called interferon gamma receptor in these cells preserves the potent anti-leukemia activities while inhibiting GvHD. Dr. Choi's Rays of Hope St. Baldrick’s Research Grant aims to identify the mechanism underlying the actions of this gene to develop safe and efficient therapeutic strategies.

This grant is named for the Rays of Hope Hero Fund which honors the memory of Rayanna Marrero by giving hope through research funding. She is remembered for her infectious smile and energetic spirit which continue to inspire so many.

Based on progress to date, Dr. Wasswa was awarded a new grant in 2018 to fund an additional year of this International Scholar grant. Whereas more than 80% of children with leukemia and lymphoma in the United States are cured with chemotherapy, in Africa a diagnosis with one of these diseases is an outright death sentence. To enable adaptation of chemotherapy protocols from the U.S. to treating children in Africa, Dr. Wasswa is studying the prevalent types of leukemia and lymphoma in children in Malawi and how their genetic code may affect response to chemotherapy.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

Ewing sarcoma is the second most common bone tumor in children and adolescents, and overall survival is dismal for patients with recurrent disease. Dr. Shelat recently identified an "Achilles’ heel" in this cancer, and showed that exploiting this weakness using a three drug cocktail cured the disease more than 80% of the time in models. This project is to validate this weakness as a marker for sensitivity to the drug cocktail in Ewing sarcoma and other pediatric cancers, and to find new drug combinations that better target this weakness.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.